CD3+, CD4+ and CD8+ T-cells are being described along with the presence of CD68+ macrophages, the presence of MHC class I antigens (HLA-A, B and C), the presence of HLA-DR, the expression of tumor-associated antigens (e.g. NY-ESO-1, mesothelin or survivin) to test for T-cell responses directed against non-mutant target antigens, as well as molecules associated with immune-suppression/evasion (e.g. PD-1, PDL-1 and CD47) along with the description if immune cells reside within the tumor or rather around, as single cells, or in clusters (Figure 8). This evidence concerns the gene CD47 and neoplasm.